James Dentzer - Curis CFO
| CRIS Stock | USD 4.03 0.07 1.71% |
CFO
Mr. James E. Dentzer is President, Chief Executive Officer, Director of the Company. Mr. Dentzer has served as the Companys chief financial officer, chief operating officer, secretary and treasurer since March 2018, and prior to that served as the Companys chief financial officer, chief administrative officer, secretary and treasurer from March 2016 until March 2018. He will continue to serve as the Companys secretary and treasurer. Mr. Dentzer previously served as chief financial officer of Dicerna Pharmaceuticals, Inc., an RNA interferencebased biopharmaceutical company, from December 2013 to December 2015. Prior to that, he was the chief financial officer of Valeritas, Inc., a commercialstage medical technology company, from March 2010 to December 2013. Prior to joining Valeritas, Inc., he was the chief financial officer of Amicus Therapeutics, Inc., a biotechnology company, from October 2006 to October 2009. In prior positions, he spent six years as corporate controller of Biogen and six years in various senior financial roles at E.I. du Pont de Nemours and Company in the U.S. and Asia since 2018.
| Age | 57 |
| Tenure | 6 years |
| Professional Marks | MBA |
| Address | Building C, Lexington, MA, United States, 02421 |
| Phone | 617 503 6500 |
| Web | https://www.curis.com |
James Dentzer Latest Insider Activity
Tracking and analyzing the buying and selling activities of James Dentzer against Curis stock is an integral part of due diligence when investing in Curis. James Dentzer insider activity provides valuable insight into whether Curis is net buyers or sellers over its current business cycle. Note, Curis insiders must abide by specific rules, including filing SEC forms every time they buy or sell Curis'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
James Dentzer over two months ago Disposition of 2406 shares by James Dentzer of Curis at 3.18 subject to Rule 16b-3 |
Curis Management Efficiency
The company has return on total asset (ROA) of (0.4597) % which means that it has lost $0.4597 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (3.7268) %, meaning that it created substantial loss on money invested by shareholders. Curis' management efficiency ratios could be used to measure how well Curis manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.73 in 2024. Return On Capital Employed is likely to drop to -0.8 in 2024. At this time, Curis' Total Assets are comparatively stable compared to the past year. Total Current Assets is likely to gain to about 64.2 M in 2024, whereas Non Currrent Assets Other are likely to drop slightly above 1.3 M in 2024.Similar Executives
| Found 4 records | CFO Age | ||
| Thomas Bures | Pieris Pharmaceuticals | 49 | |
| Adam Mostafa | X4 Pharmaceuticals | 44 | |
| Fletcher Payne | Aptose Biosciences | 61 | |
| Douglas JD | Leap Therapeutics | 55 | |
Management Performance
| Return On Equity | -3.73 | ||||
| Return On Asset | -0.46 |
Curis Inc Leadership Team
Elected by the shareholders, the Curis' board of directors comprises two types of representatives: Curis inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Curis. The board's role is to monitor Curis' management team and ensure that shareholders' interests are well served. Curis' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Curis' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Jonathan Zung, Chief Officer | ||
| Reinhard MD, Senior Development | ||
| Elif McDonald, VP Communications | ||
| James Dentzer, CFO, Chief Administrative Officer, Treasurer, Secretary | ||
| Mark Noel, Vice Property |
Curis Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Curis a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -3.73 | ||||
| Return On Asset | -0.46 | ||||
| Operating Margin | (4.91) % | ||||
| Current Valuation | 17.12 M | ||||
| Shares Outstanding | 8.47 M | ||||
| Shares Owned By Insiders | 6.77 % | ||||
| Shares Owned By Institutions | 24.36 % | ||||
| Number Of Shares Shorted | 137.03 K | ||||
| Price To Earning | (3.21) X | ||||
| Price To Book | 4.32 X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Curis Stock Analysis
When running Curis' price analysis, check to measure Curis' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Curis is operating at the current time. Most of Curis' value examination focuses on studying past and present price action to predict the probability of Curis' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Curis' price. Additionally, you may evaluate how the addition of Curis to your portfolios can decrease your overall portfolio volatility.